On December 10, 2021, Kolon Life Science Inc. closed the transaction. The company has raised KRW 25,000,000,000 in its Series 3 unregistered coupon nonguaranteed private convertible bond in final tranche bringing total proceeds to KRW 40,000,000,000.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
22,600 KRW | +1.12% | +2.96% | -12.06% |
1st Jan change | Capi. | |
---|---|---|
-12.06% | 184M | |
+41.73% | 739B | |
+32.34% | 598B | |
-5.87% | 353B | |
+17.37% | 318B | |
+3.30% | 285B | |
+16.47% | 240B | |
+9.26% | 210B | |
-5.07% | 206B | |
+6.31% | 164B |
- Stock Market
- Equities
- A102940 Stock
- News Kolon Life Science Inc.
- Kolon Life Science Inc. announced that it has received KRW 40 billion in funding